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Background
Vaccine-mediated prevention of primary infection with
HIV likely requires the sustained production of antibody
at mucosal portals of entry. We determined the dynamics
of systemic and mucosal antibody production in
macaques following a novel approach of repeat mucosal
immunisation by delivery of trimeric recombinant HIV-
1<ZM96> clade C gp140 in a gel formulated for vaginal
delivery either alone or in combination with systemic
immunisation via the intramuscular route using adjuvan-
ted gp 140.
Methods
Cynomolgus macaques received either 3 rounds of repeat
intravaginal (ivag) immunisation with gp140 formulated
in Carbopol® 974P polymer gel, followed by a single intra-
muscular (im) immunisation with 100 μg gp140 in GSK
Biologicals AS01b adjuvant (Group A); a single im immu-
nisation alone (Group B), a single im immunisation fol-
lowed by one round of ivag immunisation (Group C); or
3 im immunisations followed by one round of ivag
immunisation (Group D). Serum, vaginal and cervical
secretions were analysed for specific and total antibody by
ELISA. Virus neutralising activity was assayed with heter-
ologous clade C, HIV-1cm9. Tissue resident cells were
analysed for specific IgG and IgA antibody production by
ELISpot.
Results
Two of 4 animals in Group A made IgG and IgA antibody
responses following multiple rounds of ivag immunisa-
tion that were subsequently boosted by im immunisation.
No evidence of an anamnestic serum antibody response
was seen in the other two animals, although anti-gp140
IgG secreting cells were detected in the iliac lymph nodes.
In contrast, a single im immunisation primed IgG and IgA
responses that were boosted by a single round of ivag
immunisation (Group C), whereas; ivag immunisation
appeared not to augment antibody responses following 3
im immunisations. Virus neutralising activity was
detected in serum ranging in titre from 16 to 269.
Conclusion
Generation of vaginal antibody against HIV gp140 follow-
ing ivag administration is augmented by low-level sys-
temic priming.
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